sur GENSIGHT BIOLOGICS S.A. (EPA:SIGHT)
GenSight Biologics Reports 2025 Financial Performance
GenSight Biologics has released its estimated consolidated financial results for 2025. The year marked a significant pivot for the biopharma company, achieving key regulatory milestones. Furthermore, the company projects its cash runway to last until December 2026, amid preparations for the Phase III RECOVER study.
Financially, GenSight recorded an operating income of €0.7 million, reflecting a decline from €2.6 million in 2024 due to reduced research tax credits. The operating loss decreased by 30.1% to €11.1 million, attributed to decreased research and development expenses, which fell by 47.9%.
Despite a challenging fundraising environment, GenSight completed several financing rounds. Net cash flows from financing were €8.9 million, down from €13.5 million in 2024. However, they successfully extended their financial runway by securing various capital increases throughout the year.
Looking ahead, though revenues from early access programs are anticipated to cover operational expenses, additional funding will be necessary for the upcoming Phase III clinical trial.
R. E.
Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de GENSIGHT BIOLOGICS S.A.